Renal Dysfunction

Kidney dysfunction may play a key role in hospital death and the outcome of thrombolysis in patients who have experienced a stroke, according to a recently published study.

Real-world data showed that Bruton tyrosine kinase inhibitors were a reasonable therapeutic option for patients with chronic lymphocytic leukemia and severe renal impairment, including for older adults and those on dialysis.

Dermatologists should be aware of cutaneous findings in patients with systemic sclerosis sine scleroderma due to the association of internal organ dysfunction, according to a study.

In this Healio | Cardiology Today video exclusive, Chad Morreale, DO, discusses his presentation at the National Lipid Association Scientific Sessions: “Cardiometabolic Disease Patient – How Do I Approach Residual Risk?”

Declines in renal function observed during transition from a renin-angiotensin system inhibitor to sacubitril/valsartan for HF are variable but usually small and partially recoverable for most patients, researchers reported.

Among Japanese patients with atrial fibrillation, elevated urinary protein may be an independent risk factor for HF events, according to a study published in European Heart Journal - Quality of Care and Clinical Outcomes.

After a minor stroke or transient ischemic attack, patients with normal vs. impaired renal function treated with ticagrelor plus aspirin had lower risk for stroke at 90 days compared with clopidogrel plus aspirin, researchers reported.

Allena Pharmaceuticals Inc. announced its ALLN-346 Phase 2a Study 202 examining ALLN-346 treatment in patients with gout and advanced chronic kidney disease has completed enrollment for cohorts A and B.

Patients with normal renal function who have tested positive for COVID-19 and are undergoing chest CT angiography may not have an increased risk for contrast-associated AKI.